| 1 |
Peng X, Zeng W, Tang B, He A, Zhang M, Luo R. Utility of Pretreatment Blood Platelet-To-Lymphocyte Ratio in Prediction of Clinical Outcomes and Chemosensitivity in Patients with Advanced Gastric Cancer: A Meta-Analysis. Med Sci Monit 2022;28:e933449. [PMID: 35095093 DOI: 10.12659/MSM.933449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 2 |
Wang Z, Yang B. Polypharmacology in Clinical Applications—Anticancer Polypharmacology. Polypharmacology 2022. [DOI: 10.1007/978-3-031-04998-9_3] [Reference Citation Analysis]
|
| 3 |
Hironaka S, Sadachi R, Machida N, Iwasa S, Yamada Y, Sasako M, Yoshikawa T, Boku N, Terashima M. Association of renal function with the safety and efficacy of cisplatin plus S-1 therapy and docetaxel plus cisplatin plus S-1 therapy in patients with advanced gastric cancer: an exploratory analysis of JCOG1013. Jpn J Clin Oncol 2021:hyab160. [PMID: 34668562 DOI: 10.1093/jjco/hyab160] [Reference Citation Analysis]
|
| 4 |
Hirahara N, Matsubara T, Kaji S, Yamamoto T, Hyakudomi R, Takai K, Ishitobi K, Uchida Y, Tajima Y. Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer. BMC Cancer 2021;21:1073. [PMID: 34598694 DOI: 10.1186/s12885-021-08795-4] [Reference Citation Analysis]
|
| 5 |
Hosoda K, Azuma M, Katada C, Ishido K, Niihara M, Ushiku H, Sakuraya M, Washio M, Wada T, Watanabe A, Harada H, Tanabe S, Koizumi W, Yamashita K, Hiki N. A phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction. Int J Clin Oncol 2020;25:1090-7. [PMID: 32124094 DOI: 10.1007/s10147-020-01638-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Ohe Y, Fushida S, Yamaguchi T, Kinoshita J, Saito H, Okamoto K, Nakamura K, Tajima H, Ninomiya I, Ohta T. Peripheral Blood Platelet-Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients. Cancer Manag Res 2020;12:1303-11. [PMID: 32110104 DOI: 10.2147/CMAR.S241069] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 7 |
Zhang F, Huang X, Song Y, Gao P, Zhou C, Guo Z, Shi J, Wu Z, Wang Z. Conversion Surgery for Stage IV Gastric Cancer. Front Oncol 2019;9:1158. [PMID: 31788445 DOI: 10.3389/fonc.2019.01158] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 8 |
Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, Azuma M, Sakamoto T, Shitara K, Tamura T, Chin K, Hata H, Nakamori M, Hara H, Yasui H, Katayama H, Fukuda H, Yoshikawa T, Sasako M, Terashima M. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 2019;4:501-10. [PMID: 31101534 DOI: 10.1016/S2468-1253(19)30083-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 63] [Article Influence: 13.8] [Reference Citation Analysis]
|
| 9 |
Kinoshita H, Miki A, Nakamura D, Sugiyama T, Uchida S, Tsubono M, Adachi Y. Advanced Gastric Cancer Leading to a Perforation during Neoadjuvant Chemotherapy with S-1 plus Oxaliplatin. Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi 2019;52:11-18. [DOI: 10.5833/jjgs.2017.0155] [Reference Citation Analysis]
|
| 10 |
Fujimoto D, Goi T, Koneri K, Hirono Y. RPN2 is effective biomarker to predict the outcome of combined chemotherapy docetaxel and cisplatin for advanced gastric cancer. Oncotarget 2018;9:15208-18. [PMID: 29632637 DOI: 10.18632/oncotarget.24622] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 11 |
Ushiku H, Yamashita K, Ema A, Minatani N, Kikuchi M, Kojo K, Yokoi K, Tanaka T, Nishizawa N, Ishii S, Hosoda K, Moriya H, Mieno H, Katada N, Kikuchi S, Katoh H, Watanabe M. DNA diagnosis of peritoneal fluid cytology test by CDO1 promoter DNA hypermethylation in gastric cancer. Gastric Cancer 2017;20:784-92. [PMID: 28243814 DOI: 10.1007/s10120-017-0697-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 12 |
Saito H, Fushida S, Miyashita T, Oyama K, Yamaguchi T, Tsukada T, Kinoshita J, Tajima H, Ninomiya I, Ohta T. Potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated with preoperative docetaxel, cisplatin and S-1: a retrospective observational study. BMC Cancer. 2017;17:294. [PMID: 28449652 DOI: 10.1186/s12885-017-3279-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 13 |
Ito S, Sano T, Mizusawa J, Takahari D, Katayama H, Katai H, Kawashima Y, Kinoshita T, Terashima M, Nashimoto A, Nakamori M, Onaya H, Sasako M. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer 2017;20:322-31. [PMID: 27299887 DOI: 10.1007/s10120-016-0619-z] [Cited by in Crossref: 71] [Cited by in F6Publishing: 75] [Article Influence: 11.8] [Reference Citation Analysis]
|
| 14 |
Maeda O, Matsuoka A, Miyahara R, Funasaka K, Hirooka Y, Fukaya M, Nagino M, Kodera Y, Goto H, Ando Y. Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study. World J Gastroenterol 2017; 23(6): 1090-1097 [PMID: 28246483 DOI: 10.3748/wjg.v23.i6.1090] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Ito S, Ito Y, Misawa K, Shimizu Y, Kinoshita T. Neoadjuvant chemotherapy followed by surgery in gastric cancer patients with extensive lymph node metastasis. World J Clin Oncol 2015; 6(6): 291-294 [PMID: 26677442 DOI: 10.5306/wjco.v6.i6.291] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 16 |
Kinoshita J, Fushida S, Tsukada T, Oyama K, Okamoto K, Makino I, Nakamura K, Miyashita T, Tajima H, Takamura H, Ninomiya I, Ohta T. Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage IV gastric cancer. Eur J Surg Oncol 2015;41:1354-60. [PMID: 26028256 DOI: 10.1016/j.ejso.2015.04.021] [Cited by in Crossref: 35] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 17 |
Bae WK, Hwang JE, Shim HJ, Cho SH, Lee KH, Han HS, Song EK, Yun HJ, Cho IS, Lee JK, Lim SC, Chung WK, Chung IJ. Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck. BMC Cancer 2013;13:102. [PMID: 23497365 DOI: 10.1186/1471-2407-13-102] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 18 |
Tada Y, Maruya SI, Saotome T, Miura K, Masubuchi T, Fushimi C, Okamoto I, Takeishi E, Yamada S, Asai H, Kamata SE. Phase I/II study of docetaxel, cisplatin and S-1 in locally advanced, recurrent and metastatic head and neck squamous cell carcinoma. Oncol Lett 2012;4:898-904. [PMID: 23162619 DOI: 10.3892/ol.2012.846] [Reference Citation Analysis]
|
| 19 |
Cui Y, Li Q, Yu Y, Chen Y, Feng Y, Wang Y, Liu T. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor. Cancer Chemother Pharmacol 2013;71:145-52. [PMID: 23064955 DOI: 10.1007/s00280-012-1991-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 20 |
Katayama H, Ito S, Sano T, Takahari D, Mizusawa J, Boku N, Tsuburaya A, Terashima M, Sasako M; Stomach Cancer Study Group of the Japan Clinical Oncology Group. A Phase II study of systemic chemotherapy with docetaxel, cisplatin, and S-1 (DCS) followed by surgery in gastric cancer patients with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1002. Jpn J Clin Oncol 2012;42:556-9. [PMID: 22525210 DOI: 10.1093/jjco/hys054] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 21 |
Yamaguchi K, Katsube T, Miyaki A, Murayama M, Usuda A, Isohata N, Asaka S, Shimakawa T, Naritaka Y, Ogawa K. Therapeutic Outcome in Advanced Gastric Cancer Undergoing S−1+CDDP Combined Neoadjuvant Chemotherapy. JJCS 2012;37:205-209. [DOI: 10.4030/jjcs.37.205] [Reference Citation Analysis]
|
| 22 |
Yamasaki Y, Fushida S, Oyama K, Kinoshita J, Makino I, Nakamura K, Fujita H, Ninomiya I, Fujimura T, Ohta T. A Case of Advanced Gastric Cancer Responding to Neoadjuvant Chemotherapy. Jpn J Gastroenterol Surg 2012;45:258-266. [DOI: 10.5833/jjgs.45.258] [Reference Citation Analysis]
|
| 23 |
Oyama K, Fushida S, Kinoshita J, Makino I, Nakamura K, Hayashi H, Nakagawara H, Tajima H, Fujita H, Takamura H, Ninomiya I, Kitagawa H, Tani T, Fujimura T, Ohta T. Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and S-1 (DCS therapy) and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes. J Surg Oncol. 2012;105:535-541. [PMID: 22006649 DOI: 10.1002/jso.22125] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 24 |
Koizumi W, Nakayama N, Tanabe S, Sasaki T, Higuchi K, Nishimura K, Takagi S, Azuma M, Ae T, Ishido K, Nakatani K, Naruke A, Katada C. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemother Pharmacol. 2012;69:407-413. [PMID: 21796483 DOI: 10.1007/s00280-011-1701-1] [Cited by in Crossref: 57] [Cited by in F6Publishing: 63] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 25 |
Tahara M, Araki K, Okano S, Kiyota N, Fuse N, Minashi K, Yoshino T, Doi T, Zenda S, Kawashima M, Ogino T, Hayashi R, Minami H, Ohtsu A. Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancer. Annals of Oncology 2011;22:175-80. [DOI: 10.1093/annonc/mdq298] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 26 |
Hashimoto I, Nashimoto A, Yabusaki H, Nakagawa S, Matsuki A. A Case of Advanced Gastric Cancer with Abdominal Paraaortic and Virchow's Lymph Node Metastasis Responding to Pathological CR After Preoperative Combined Docetaxel, Cisplatin, and S^|^ndash;1 Chemotherapy. JJCS 2011;36:796-801. [DOI: 10.4030/jjcs.36.796] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 27 |
Fujii M, Kochi M, Takayama T. Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today. 2010;40:295-300. [PMID: 20339982 DOI: 10.1007/s00595-009-4148-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 28 |
Fushida S, Fujimura T, Oyama K, Yagi Y, Kinoshita J, Ohta T. Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases. Anticancer Drugs. 2009;20:752-756. [PMID: 19543076 DOI: 10.1097/cad.0b013e32832ec02b] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
|
